Home LiteratureArticle Details
PMID: 21675881 Published · ppublish English Journal Article

Weighing the benefits of high-dose simvastatin against the risk of myopathy.

The New England journal of medicine ·Vol. 365 ·No. 4 ·2011-07-28 ·Pages 285-7

Egan A, Colman E

Abstract

暂无摘要

MeSH Terms
Anticholesteremic Agents/administration & dosage,adverse effects Creatine Kinase/blood Drug Approval Drug Interactions Drug Labeling Dyslipidemias/drug therapy Humans Muscular Diseases/chemically induced Risk Simvastatin/administration & dosage,adverse effects United States United States Food and Drug Administration
Chemicals
Anticholesteremic Agents Simvastatin Creatine Kinase
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Egan Amy
Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Colman Eric
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMp1106689
Published
2011-07-28
Epub
2011-00-15
Pages
285-7
Language
English
Region
United States
NLM ID
0255562
Subset
IM
External Links
PubMed source DOI: 10.1056/NEJMp1106689 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2